TNF Pharmaceuticals (NASDAQ:TNFA – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
Earnings and Valuation
This table compares TNF Pharmaceuticals and Altimmune”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TNF Pharmaceuticals | N/A | N/A | -$23.36 million | ($231.00) | -0.01 |
| Altimmune | $41,000.00 | 10,456.00 | -$88.09 million | ($1.01) | -3.26 |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for TNF Pharmaceuticals and Altimmune, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TNF Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Altimmune | 2 | 1 | 7 | 0 | 2.50 |
Altimmune has a consensus price target of $18.00, indicating a potential upside of 446.28%. Given Altimmune’s stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than TNF Pharmaceuticals.
Profitability
This table compares TNF Pharmaceuticals and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TNF Pharmaceuticals | N/A | -69.21% | -33.98% |
| Altimmune | -214,860.98% | -49.35% | -41.65% |
Volatility & Risk
TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.
Insider and Institutional Ownership
9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Altimmune beats TNF Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
